[ad_1]
The vaccine produced by Pfizer and BioNTech would be effective in 95% of cases in preventing SARS-CoV-2 infection, according to the final analysis of the clinical study. For people over 65, the effectiveness would be greater than 94%. The two companies that worked on this serum say that the side effects are minor. The announcement is a clear reason for hope, as it amounts to the beginning of the end of this pandemic, Gindrovel Dumitra, vice president of the National Society of Family Medicine, told Digi24.
“The news (about the effectiveness of the vaccine – no) is like the light at the end of the tunnel, it is the beginning of the end of this pandemic,” said the doctor.
According to him, it is essential to have an effective and safe vaccine.
“For us as physicians, it is important to tell our colleagues and patients that we will have a safe and effective vaccine, but we will do so after the appropriate authorities have approved the vaccines,” said Gindrovel Dumitra.
He said the announced 95% effectiveness of the vaccine was “exceptional”, especially in the case of a virus like this: “We are talking about hope. Let’s hope things turn out well.”
We have to wait for the final approvals, there are some rules imposed by the approval authorities. The company must demonstrate its effectiveness, what we have seen achieved and then the safety of adverse reactions.
We are talking about only 2% mild side effects, they are incomparable with the effects that the disease itself can produce.
The safety news is equally good, but we have to wait for the final formulas.
I think there will be more and more good news. “
A final analysis of the phase 3 study of the COVID vaccine produced by Pfizer and BioNTech shows that it was 95% effective in preventing infections, even in older adults, and did not cause serious safety concerns, the company said Wednesday. .
“Efficacy was consistent by age, race and ethnicity. The effectiveness observed in adults over 65 years was greater than 94%,” said Pfizer and its German partner BioNTech in a joint statement.
The only “adverse element” was fatigue in 3.7% of the patients.
The companies have announced that they will apply to the US authorities for emergency approval of the vaccine in the coming days. The data will also be passed on to other regulatory agencies around the world.
Based on current forecasts, companies expect to produce up to 50 million doses of vaccines globally in 2020 and up to 1.3 billion doses in 2021.
Publisher: Georgiana Marina
